Clinical trials: Injection Site, open to volunteers
Ovarian Cancer
SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
This study is a randomized, open-label, controlled, phase III study to evaluate the efficacy and safety of SHR-A1921 versus investigator's choice of chemotherapy in patients with platinum-resistant recurrent epithelial ovarian…
- Trial name
- NCT06394492
- Testing
- SHR-A1921, Doxorubicin, Paclitaxel
- Where
- 2 sites in China
- Volunteers
- 440 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Malignant Mesothelioma, Mesothelioma
Study of Iparomlimab and Tuvonralimab Plus Chemotherapy in Malignant Mesothelioma
This clinical trial aims to investigate the effectiveness and safety of a new treatment combination-Iparomlimab and Tuvonralimab (QL1706, a dual-function antibody targeting PD-1 and CTLA-4) combined with chemotherapy-for patients…
- Trial name
- NCT07131345
- Testing
- iparomlimab and tuvonralimab (Dual PD-1/CTLA-4 blockade) + chemotherapy
- Volunteers
- 55 people
- Sponsor
- National Cancer Center, China
Hepatoma, Unresectable Hepatocellular Carcinoma (HCC)
MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.
The main purpose of the study is to evaluate the safety and efficacy of MDN-001 injection(Yttrium-90 Microsphere Injection)in the treatment of unresectable hepatocellular carcinoma.
- Trial name
- NCT07391839
- Testing
- MDN-001 Injection(Yttrium-90 Microsphere Injection)
- Where
- 8 sites in China
- Volunteers
- 40 people
- Sponsor
- Suzhou Mednovo Yi Medical Technology Co., Ltd.
Triple Negative Breast Cancer
to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC)
This study is a randomized, double-Blind,international multi-Centre, phase III clinical study to evaluate efficacy and safety of HLX10 in combination with chemotherapy versus placebo in combination with chemotherapy as…
- Trial name
- NCT04301739
- Testing
- HLX10, nab-paclitaxel, carboplatin, doxorubicin or epirubicin and cyclophosphamide
- Volunteers
- 522 people
- Sponsor
- Shanghai Henlius Biotech
Non-Small Cell Lung Cancer
SDTM001 Injection as Adjuvant Therapy for NSCLC Patients After Radical Surgical Resection
The goal of this clinical trial is to evaluate the safety profile and tolerability of SDT-M001 injection in NSCLC patients with driver-gene-negative and negative PD-L1 expression after radical surgical resection; to determine the…
- Trial name
- NCT07096882
- Testing
- SDT-M001 injection
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Cytocraft Biopharmaceutical Co., Ltd.
Gynecological Malignant Tumor, Solid Tumor
A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies
A phase Ib/II clinical study to evaluate the safety, tolerability, pharmacokinetics and efficacy of BL-B01D1 for injection in patients with multiple solid tumors, including recurrent or metastatic gynecological malignancies.
- Trial name
- NCT05803018
- Testing
- BL-B01D1
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Prostate Cancer
Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Patients With Prostate Cancer.
A multicenter, open-label, prospective Phase III clinical trial to evaluate INR101 injection for PET/CT imaging in patients with Prostate Cancer
- Trial name
- NCT06922903
- Testing
- INR101
- Where
- 32 sites in China
- Volunteers
- 240 people
- Sponsor
- Yunhe Pharmaceutical (Tianjin) Co., Ltd
Small Cell Carcinoma of Lung
A Clinical Study for the Safety and Efficacy of BL0020 Injection in Combination With Toripalimab Injection in Patients With Recurrent Extensive-Stage Small Cell Lung Cancer
Lung cancer remains the leading cause of cancer deaths worldwide; in 2022, there were approximately 2.48 million new cases and 1.8 million deaths from lung cancer globally.
- Trial name
- NCT07550842
- Testing
- BL0020, Toripalimab
- Where
- 8 sites in China
- Volunteers
- 33 people
- Sponsor
- Shanghai Best-Link Bioscience, LLC
HIV I Infection, Injection Pain
Impact of Pain From Injectables Antiretroviral Treatments in HIV-1 Patients Based on the Injection Site (Ventrogluteal or Dorsogluteal) and the Use or Non-use of Virtual Reality Headset
This is a multicenter, randomized, open-label study with a cross-over design. The objective of this project is to compare the intensity of pain induced by injectable antiretroviral (ARV) treatment (Cabotegravir® and Rilpivirine®)…
- Trial name
- VIHINJECT (NCT06834113)
- Testing
- Dorsogluteal intramuscular injection
- Where
- 5 sites in France
- Volunteers
- 120 people
- Sponsor
- Centre Hospitalier Régional d'Orléans
Hepatocellular Carcinoma
Yttrium-90 Carbon Microsphere Radioembolization in Previously Treated Hepatocellular Carcinoma
This is a prospective, open-label, single-arm, investigator-initiated study designed to evaluate the safety and efficacy of NRT6003 Injection, a yttrium-90 carbon microsphere product, administered by selective internal radiation…
- Trial name
- NCT07657273
- Testing
- NRT6003 Injection
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Melanoma, Acral Melanoma
A Study of QL1706 Combined With OH2 Injection in Perioperative Treatment of Stage III Resectable Acral Melanoma
This is a prospective, multicenter, open-label, 1:1 randomized phase II trial enrolling 76 patients with AJCC stage III surgically resectable acral melanoma.
- Trial name
- NCT07854522
- Testing
- Iparomlimab and Tuvonralimab Injection (QL1706), OH2 Injection(Recombinant Human GM-CSF Oncolytic Type II Herpes Simplex Virus)
- Volunteers
- 76 people
- Sponsor
- Peking University Cancer Hospital & Institute
Hematologic Malignancy
CD7-specific CAR-T Cell in the Treatment of CD7-positive Relapsed/Refractory Hematologic Tumors
This study is a single-center, open, prospective single-arm clinical study of patients with CD7 postive relapsed / refractoryhematological tumors to evaluate the safety and efficacy of CD7-specific CAR-T cells in relapsed /…
- Trial name
- NCT06720324
- Testing
- Fludarabine + Cyclophosphamide + CD7-specific CAR-T Cells
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Quality of Life, Breast Neoplasms
Improved Facial Skin Quality and Quality of Life After VYC-12L Treatment in Breast Cancer Survivors
Systemic treatments such as chemotherapy or monoclonal antibodies are an essential part of oncological treatment in breast cancer, which have demonstrated a survival benefit (1,2,3,4,5).
- Conditions
- Quality of Life, Breast Neoplasms, Skin Aging, Hyaluronic Acid
- Trial name
- ONCO AESTHETIC (NCT07917117)
- Testing
- Intradermal injection
- Where
- Spain
- Volunteers
- 50 people
- Sponsor
- Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
Solid Tumor, Gastrointestinal Cancer
OH2 Oncolytic Viral Therapy in Solid Tumors
This phase I/II study evaluates the safety and efficacy of OH2 as single agent or in combination with HX008, an anti-PD-1 antibody, in patients with malignant solid tumors (gastrointestinal cancers, head and neck cancers, soft…
- Trial name
- NCT03866525
- Testing
- OH2 injection, with or without irinotecan or HX008
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Binhui Biopharmaceutical Co., Ltd.
Pancreatic Cancer
A Phase I Clinical Study of IX001 TCR-T Injection in the Treatment of Advanced Pancreatic Cancer Patients With KRAS G12V Mutation
This is a single-arm, open-label clinical study to evaluate the safety, tolerability and preliminary efficacy of IX001 TCR-T injection in advanced pancreatic cancer patients with KRAS G12V mutation.
- Trial name
- IX001 TCR-T (NCT06898385)
- Testing
- IX001 TCR-T injection, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Sun Yat-sen University
Gastric Cancer, Metastatic
A Clinical Study of BioTTT001 in Combination With SOX and Toripalimab in Patients With Gastric Cancer
This is a phase I, single arm, open-label clinical study of BioTTT001 in combination with SOX and Toraplizumab in patients with peritoneal metastases from gastric cancer.
- Trial name
- NCT06283121
- Testing
- BioTTT001 intraperitoneal infusion, SOX regimen, toripalimab
- Volunteers
- 30 people
- Sponsor
- China Medical University, China
Ovarian Cancer, Mesothelioma
An Open-label, Single-arm Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of KT032 Cell Injection in Patients With Mesothelin-positive Advanced Solid Tumors.
An Open-label, Single-arm Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of KT032 Cell Injection in Patients With Mesothelin-positive Advanced Solid Tumors.
- Conditions
- Ovarian Cancer, Mesothelioma, Colon Cancer
- Trial name
- NCT07420010
- Testing
- KT032(anti-MSLN chimeric antigen receptor autologous T cell injection)
- Volunteers
- 24 people
- Sponsor
- Weijia Fang, MD
Shoulder Arthroscopy, Postoperative Pain
Injection Site in Ultrasound-Guided Interscalene Block for Shoulder Arthroscopy
Ultrasound-guided interscalene block is commonly used for postoperative analgesia in patients undergoing shoulder arthroscopy. The location of local anesthetic injection may influence both block efficacy and the incidence of…
- Trial name
- ISB-ROOT (NCT07695025)
- Testing
- Ultrasound-Guided Interscalene Block
- Where
- Turkey (Türkiye)
- Volunteers
- 50 people
- Sponsor
- Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey
Rectal Cancer
Neoadjuvant Chemoradiotherapy Combined With Immunotherapy and Anti-angiogenesis in Treating Locally Advanced Rectal Cancer
This is a multicenter, prospective, randomized phase II trial designed to evaluate the efficacy and safety of short-course neoadjuvant chemoradiotherapy combined with the PD-1 monoclonal antibody serplulimab and the…
- Trial name
- NCT07134218
- Testing
- serplulimab、bevacizumab, neoadjuvant chemoradiation therapy
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Changhai Hospital
Hepatocellular Carcinoma (HCC)
Clinical Study of SN301A Injection in the Treatment of Hepatocellular Carcinoma
This is a single-arm, open-label study of safety, tolerability, and anti-cancer activity of SN301A (an off-the-shelf CAR NK cell therapy) in patients with glypican-3 (GPC3)-positive advanced hepatocellular carcinoma.
- Trial name
- SN301A (NCT06652243)
- Testing
- SN301A
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine